Evaluation of safety and efficacy of ZD1839 as monotherapy for Chinese patients with advanced non-small cell lung cancer.

被引：0
|
作者：
Zhang, XT [1 ]
Li, L [1 ]
机构：
[1] CAMS, Peking Union Med Coll Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7093
引用
收藏
页码：639S / 639S
页数：1
相关论文
共 50 条
  • [41] Management of cutaneous adverse effects during treatment with ZD1839 in advanced non-small cell lung cancer (NSCLC): Surprising efficacy of early local treatment.
    Cortesi, E
    Ceratti, AD
    D'Auria, G
    Nelli, F
    Evangelista, ML
    Mazzoli, M
    Di Fonzo, C
    Pizzardi, N
    Picone, V
    Lugini, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 641S - 641S
  • [42] Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor
    Lee, MW
    Seo, CW
    Kim, SW
    Yang, HJ
    Lee, HW
    Choi, JH
    Moon, KC
    Koh, JK
    [J]. ACTA DERMATO-VENEREOLOGICA, 2004, 84 (01) : 23 - 26
  • [43] A Two Center Phase 1 Study Assessing the Safety of ZD1839 (GEFITINIB) Plus Palliative Thoracic Radiotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
    Williamson, D. K.
    Snee, M.
    Franks, K.
    Price, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S452 - S452
  • [44] Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer
    Zhu Yu-jia
    Xia Ying
    Ren Guan-jun
    Wang Meng-zhao
    Zeng Xuan
    Zhang Li
    [J]. CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3200 - 3205
  • [45] Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer A Phase II Study
    Kubota, Kaoru
    Nishiwaki, Yutaka
    Tamura, Tomohide
    Nakagawa, Kazuhiko
    Matsui, Kaoru
    Watanabe, Koshiro
    Hida, Toyoaki
    Kawahara, Masaaki
    Katakami, Nobuyuki
    Takeda, Kohi
    Yokoyama, Akira
    Noda, Kazumasa
    Fukuoka, Masahiro
    Saijo, Nagahiro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (12) : 1439 - 1445
  • [46] Advanced non-small cell lung cancer.
    Edelman M.J.
    Khanwani S.L.
    [J]. Current Treatment Options in Oncology, 2001, 2 (1) : 51 - 62
  • [47] Circadian variation in nivolumab efficacy in patients with advanced non-small cell lung cancer.
    Karabou, Abdoulaye
    Bisseux, Laurence
    Pavese, Ida
    Collon, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Efficacy, tolerability and improvement of symptoms in heavily pretreated patients with locally advanced or metastatic non-small-cell lung cancer treated with gefitinib ('Iressa', ZD1839)
    Petersen, V
    Grau, P
    Schneller, F
    Peschel, C
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S32 - S32
  • [49] Phase II trial ZD1839 (IRESSA™) secound-third line in patients with advanced/metastatic non-small cell lung cancer (NSCLC): preliminary results
    Adamo, Vincenzo
    Scimone, Antonio
    Spitaleri, Gianluca
    Altavilla, Giuseppe
    Marabello, Grazia
    Adamo, Barbara
    Scandurra, Giuseppa
    Zanghi, Mariangela
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 195 - 195
  • [50] Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program
    Razis, E
    Skarlos, D
    Briasoulis, E
    Dimopoulos, M
    Fountzilas, G
    Lambropoulos, S
    Rigatos, S
    Kopterides, P
    Efstathiou, H
    Tzamakou, E
    Bakoyannis, C
    Pectasides, D
    Makatsoris, T
    Varthalitis, G
    Papadopoulos, S
    Kosmidis, R
    [J]. ANTI-CANCER DRUGS, 2005, 16 (02) : 191 - 198
12345